Proteus mirabilis urinary tract infection and bacteremia: Risk factors, clinical presentation, and outcomes

Journal of Microbiology, Immunology and Infection

Volumn 45, Issue 3, 2012, Pages 228-236

  Chen, Chi Yu ^a   Chen, Yen Hsu ^a,b,c   Lu, Po Liang ^a,b,c   Lin, Wei Ru ^a   Chen, Tun Chieh ^a,b,c   Lin, Chun Yu ^a,b,c  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Bacteremia; Multidrug resistance; Proteus mirabilis; Urinary tract infection

Indexed keywords

AMINOGLYCOSIDE; C REACTIVE PROTEIN; CEPHALOSPORIN; COTRIMOXAZOLE; CREATININE; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

AGE; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BLADDER CATHETERIZATION; BODY MASS; BODY TEMPERATURE; CASE CONTROL STUDY; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; FEMALE; GENDER; HOSPITAL INFECTION; HUMAN; HYDRONEPHROSIS; HYPERTHERMIA; HYPOTHERMIA; INFECTION RISK; INTENSIVE CARE UNIT; KIDNEY FAILURE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MORTALITY; NEUTROPHIL COUNT; PROTEIN BLOOD LEVEL; PROTEUS INFECTION; PROTEUS MIRABILIS; PULSE RATE; RETROSPECTIVE STUDY; RISK ASSESSMENT; SHOCK; UREMIA; URINARY TRACT INFECTION;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PROTEUS INFECTIONS; PROTEUS MIRABILIS; RETROSPECTIVE STUDIES; RISK FACTORS; TAIWAN; URINARY TRACT INFECTIONS;

EID: 84861231390     PISSN: 16841182     EISSN: 19959133     Source Type: Journal    
DOI: 10.1016/j.jmii.2011.11.007     Document Type: Article

References (39)

1. Mobley H.L., Belas R. Swarming and pathogenicity of Proteus mirabilis in the urinary tract. Trends Microbiol 1995, 3:280-284.
2. Pearson M.M., Sebaihia M., Churcher C., Quail M.A., Seshasayee A.S., Luscombe N.M., et al. Complete genome sequence of uropathogenic Proteus mirabilis: a master of both adherence and motility. J Bacteriol 2008, 190:4027-4037.
3. Harrison L.H., Cass A.S., Bullock B.C., Cox C.E. Experimental pyelonephritis in dogs: confirmation by antibody response. J Urol 1973, 109:163-166.
4. Warren J.W., Tenney J.H., Hoopes J.M., Muncie H.L., Anthony W.C. A prospective microbiologic study of bacteriuria in patients with chronic indwelling urethral catheters. J Infect Dis 1982, 146:719-723.
5. Broomfield R.J., Morgan S.D., Khan A., Stickler D.J. Crystalline bacterial biofilm formation on urinary catheters by urease-producing urinary tract pathogens: a simple method of control. J Med Microbiol 2009, 58:1367-1375.
6. Kunin C.M. Blockage of urinary catheters: role of microorganisms and constituents of the urine on formation of encrustations. J Clin Epidemiol 1989, 42:835-842.
7. Thornsberry C., Yee Y.C. Comparative activity of eight antimicrobial agents against clinical bacterial isolates from the United States, measured by two methods. Am J Med 1996, 100:26S-38S.
8. Karlowsky J.A., Jones M.E., Thornsberry C., Friedland I.R., Sahm D.F. Trends in antimicrobial susceptibilities among Enterobacteriaceae isolated from hospitalized patients in the United States from 1998 to 2001. Antimicrob Agents Chemother 2003, 47:1672-1680.
9. Lockhart S.R., Abramson M.A., Beekmann S.E., Gallagher G., Riedel S., Diekema D.J., et al. Antimicrobial resistance among Gram-negative bacilli causing infections in intensive care unit patients in the United States between 1993 and 2004. J Clin Microbiol 2007, 45:3352-3359.
10. Giamarellos-Bourboulis E.J., Papadimitriou E., Galanakis N., Antonopoulou A., Tsaganos T., Kanellakopoulou K., et al. Multidrug resistance to antimicrobials as a predominant factor influencing patient survival. Int J Antimicrob Agents 2006, 27:476-481.
11. Endimiani A., Luzzaro F., Perilli M., Lombardi G., Colì A., Tamborini A., et al. Bacteremia due to Klebsiella pneumoniae isolates producing the TEM-52 extended-spectrum beta-lactamase: treatment outcome of patients receiving imipenem or ciprofloxacin. Clin Infect Dis 2004, 38:243-251.
12. Kim Y.K., Pai H., Lee H.J., Park S.E., Choi E.H., Kim J., et al. Bloodstream infections by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome. Antimicrob Agents Chemother 2002, 46:1481-1491.
13. Menashe G., Borer A., Yagupsky P., Peled N., Gilad J., Fraser D., et al. Clinical significance and impact on mortality of extended-spectrum beta lactamase-producing Enterobacteriaceae isolates in nosocomial bacteremia. Scand J Infect Dis 2001, 33:188-193.
14. Wong-Beringer A., Hindler J., Loeloff M., Queenan A.M., Lee N., Pegues D.A., et al. Molecular correlation for the treatment outcomes in bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae with reduced susceptibility to ceftazidime. Clin Infect Dis 2002, 34:135-146.
15. Diekema D.J., Pfaller M.A., Jones R.N., Doern G.V., Kugler K.C., Beach M.L., et al. Trends in antimicrobial susceptibility of bacterial pathogens isolated from patients with bloodstream infections in the USA, Canada and Latin America. SENTRY Participants Group. Int J Antimicrob Agents 2000, 13:257-271.
16. Luzzaro F., Viganò E.F., Fossati D., Grossi A., Sala A., Sturla C., et al. Prevalence and drug susceptibility of pathogens causing bloodstream infections in northern Italy: a two-year study in 16 hospitals. Eur J Clin Microbiol Infect Dis 2002, 21:849-855.
17. Kim B.N., Kim N.J., Kim M.N., Kim Y.S., Woo J.H., Ryu J. Bacteraemia due to tribe Proteeae: a review of 132 cases during a decade (1991-2000). Scand J Infect Dis 2003, 35:98-103.
18. Brun-Buisson C. The epidemiology of the systemic inflammatory response. Intensive Care Med 2000, 26(Suppl. 1):S64-S74.
19. Pittet D., Rangel-Frausto S., Li N., Tarara D., Costigan M., Rempe L., et al. Systemic inflammatory response syndrome, sepsis, severe sepsis and septic shock: incidence, morbidities and outcomes in surgical ICU. Intensive Care Med 1995, 21:302-309.
20. Tal S., Guller V., Levi S., Bardenstein R., Berger D., Gurevich I., et al. Profile and prognosis of febrile elderly patients with bacteremic urinary tract infection. J Infect 2005, 50:296-305.
21. Al-Hasan M.N., Eckel-Passow J.E., Baddour L.M. Bacteremia complicating gram-negative urinary tract infections: a population-based study. J Infect 2010, 60:278-285.
22. Barkham T.M., Martin F.C., Eykyn S.J. Delay in the diagnosis of bacteraemic urinary tract infection in elderly patients. Age Ageing 1996, 25:130-132.
23. van Nieuwkoop C., Hoppe B.P., Bonten T.N., Van't Wout J.W., Aarts N.J., Mertens B.J., et al. Predicting the need for radiologic imaging in adults with febrile urinary tract infection. Clin Infect Dis 2010, 51:1266-1272.
24. Velasco M., Martinez J.A., Moreno-Martinez A., Horcajada J.P., Ruiz J., Barranco M., et al. Blood cultures for women with uncomplicated acute pyelonephritis: are they necessary?. Clin Infect Dis 2003, 37:1127-1130.
25. D'Hoore W., Sicotte C., Tilquin C. Risk adjustment in outcome assessment: the Charlson comorbidity index. Methods Inf Med 1993, 32:382-387.
26. Horan T.C., Andrus M., Dudeck M.A. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008, 36:309-332.
27. Chin B.S., Kim M.S., Han S.H., Shin S.Y., Choi H.K., Chae Y.T., et al. Risk factors of all-cause in-hospital mortality among Korean elderly bacteremic urinary tract infection (UTI) patients. Arch Gerontol Geriatr 2011, 52:e50-e55.
28. Endimiani A., Luzzaro F., Brigante G., Perilli M., Lombardi G., Amicosante G., et al. Proteus mirabilis bloodstream infections: risk factors and treatment outcome related to the expression of extended-spectrum beta-lactamases. Antimicrob Agents Chemother 2005, 49:2598-2605.
29. Performance standards for antimicrobial susceptibility testing, 18th informational supplement. NCCLS document M100-S18 2008, National Committee for Clinical Laboratory Standards, National Committee for Clinical Laboratory Standards, Wayne, PA.
30. Cohen-Nahum K., Saidel-Odes L., Riesenberg K., Schlaeffer F., Borer A. Urinary tract infections caused by multi-drug resistant Proteus mirabilis: risk factors and clinical outcomes. Infection 2010, 38:41-46.
31. Jerkeman M., Braconier J.H. Bacteremic and non-bacteremic febrile urinary tract infection: a review of 168 hospital-treated patients. Infection 1992, 20:143-145.
32. Leibovici L., Greenshtain S., Cohen O., Wysenbeek A.J. Toward improved empiric management of moderate to severe urinary tract infections. Arch Intern Med 1992, 152:2481-2486.
33. Bahagon Y., Raveh D., Schlesinger Y., Rudensky B., Yinnon A.M. Prevalence and predictive features of bacteremic urinary tract infection in emergency department patients. Eur J Clin Microbiol Infect Dis 2007, 26:349-352.
34. Berger S.A. Proteus bacteraemia in a general hospital 1972-1982. J Hosp Infect 1985, 6:293-298.
35. Watanakunakorn C., Perni S.C. Proteus mirabilis bacteremia: a review of 176 cases during 1980-1992. Scand J Infect Dis 1994, 26:361-367.
36. Hsu C.Y., Fang H.C., Chou K.J., Chen C.L., Lee P.T., Chung H.M. The clinical impact of bacteremia in complicated acute pyelonephritis. Am J Med Sci 2006, 332:175-180.
37. Le Blanc K., Ringdén O., Remberger M. A low body mass index is correlated with poor survival after allogeneic stem cell transplantation. Haematologica 2003, 88:1044-1052.
38. Lin Y.F., Ko W.J., Chu T.S., Chen Y.S., Wu V.C., Chen Y.M., et al. The 90-day mortality and the subsequent renal recovery in critically ill surgical patients requiring acute renal replacement therapy. Am J Surg 2009, 198:325-332.
39. Yang Y.S., Ku C.H., Lin J.C., Shang S.T., Chiu C.H., Yeh K.M., et al. Impact of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae on the outcome of community-onset bacteremic urinary tract infections. J Microbiol Immunol Infect 2010, 43:194-199.